ArticleJAMA oncology2021

Quantifying the Long-term Survival Benefit of Pembrolizumab for Patients With Advanced Gastric Cancer-Reply.

Kohei Shitara et al.PubMed ↗Publisher ↗

No numbers read from the abstract.